Boston-based drugmaker Vertex, which specializes in rare disorders like cystic fibrosis, doesn’t always attract Big Pharma–level attention. But the firm is on a serious growth trajectory, slated for double-digit expansion in the coming years, per analysts. And the company is branching out into new, brand-name science it hopes can add to its $43 billion market value, including a recent $950 million deal to acquire Semma Therapeutics—a startup that aims to use stem cells to cure Type 1 diabetes.
Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.
Company Information
| Overall Score | 2.6 |
| Sector | Health Care |
| Industry | Biotechnology |
| CEO | Jeffrey Leiden |
| Website | www.vrtx.com |
| HQ Location | Boston |
| Country | U.S. |
| Revenues ($M) (Past 12 Months) | $3,454 |
| Profits ($M) (Past 12 Months) | $2,215 |
| Market Value as of Oct. 9, 2019 ($M) | $43,370 |
| Employees | 2,500 |